G Protein News and Research

RSS

Brain study may lead to new forms of treatment for Alzheimer's disease

A study from EPFL's (Ecole Polytechnique F-d-rale de Lausanne) Laboratory of Neuroenergetics and Cellular Dynamics in Lausanne Switzerland, published today in the Journal of Neuroscience, may lead to new forms of treatment following a better understanding of how Amyloid-Beta found in cerebral plaques, typically present in the brain of Alzheimer's patients, may lead to neurodegeneration.

4 Mar 2010

Exposure to blue-violet light may enhance cell growth in wound sites

Today, during the 39th Annual Meeting of the American Association for Dental Research, convening at the Walter E. Washington Convention Center in Washington, DC, lead researcher C. Millan (U.S. Army Dental Corps, Martinez, Georgia) will present a poster of a study titled "A Novel In Vitro Model for Light-Induced Wound Healing."

4 Mar 2010

Pycnogenol counteracts kidney damage due to hypertension

An estimated one in ten adults suffers from kidney disease, according to the National Institute of Diabetes and Digestive and Kidney Diseases. A leading cause of kidney disease is hypertension, which effects one out of every four U.S. adults. Chronically high blood pressure damages capillaries of the kidneys which in turn affects the organ's ability to filter waste and remove excess fluids from the body.

4 Mar 2010

Cornell researchers find new protein that may help control mosquitoes from spreading diseases

Cornell researchers have found a protein that may lead to a new way to control mosquitoes that spread dengue fever, yellow fever and other diseases when they feed on humans: Prevent them from urinating as they feed on blood.

4 Mar 2010

Cystoscopy: Cost-effective method of detecting tumors

In a new study from The University of Texas M. D. Anderson Cancer Center, researchers found that cystoscopy, the standard for screening for recurrence of early-stage bladder cancer, is a cost-effective method of detecting tumors.

4 Mar 2010

Belatacept drug can prevent graft rejection in kidney transplant recipients

The experimental drug belatacept can prevent graft rejection in kidney transplant recipients while better preserving kidney function when compared with standard immunosuppressive drugs, data from two international phase III clinical trials show.

4 Mar 2010

Repligen acquires BioFlash

Repligen Corporation announced today that it has acquired the assets of BioFlash Partners, LLC, (BioFlash) including a technology platform for the production of pre-packed, "plug and play" chromatography columns. This patented technology enables economical production of chromatography columns in a format that is ready for use in the production of a broad range of biopharmaceuticals including monoclonal antibodies, vaccines and recombinant proteins.

4 Mar 2010

New chemical classes of preclinical compounds identified for Alzheimer’s disease

In an announcement today, Mount Sinai School of Medicine and Medisyn Technologies, Inc. said they have identified new chemical classes of preclinical compounds that may eventually lead to the first effective management of toxic amyloid aggregation and accumulation in the brain— an abnormal biological process long suspected by many researchers to be a major culprit in the onset and progression of Alzheimer’s disease.

4 Mar 2010

Researchers explore molecular origin of skin and hair to develop novel beauty products

Scientists at L'Or-al, in hot pursuit of the hidden elements of beauty, seem well on their way to disputing the old adage, "beauty is only skin deep." In fact, their work indicates that what makes hair curly or straight and skin smooth or rough, is much deeper.

3 Mar 2010

Gene 'addiction' of leukaemia cells

An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveals how leukaemia cells become 'addicted' to genes, which if targeted could prevent diseased cells from developing.

3 Mar 2010

Allergan celebrates 20th anniversary of BOTOX in Canada

Twenty years ago, the first approved use of BOTOX(R) (botulinum toxin type A), a neurotoxin widely used to treat several life altering medical conditions, was granted in Canada. As part of the 20th anniversary celebrations, healthcare professionals from coast to coast reflect upon the discovery, science and evolution of a therapy that has impacted the lives of millions of patients worldwide.

3 Mar 2010

Vaccine researchers at HZI find c-di-IMP molecule, more effective than known adjuvants

The adjuvants present in vaccines have a bad reputation. For most people, they are only unnecessary compounds within a medicinal product. This is a misunderstanding since adjuvants have a critical impact on the success of a vaccination. In the best case scenario, one single vaccination shot would be now sufficient for conferring life-long protection.

3 Mar 2010

Concordia University Professor awarded grant to study molecular mechanisms of virulence factor protein

Concordia University is pleased to announce that Dr. Peter D. Pawelek, Assistant Professor, Department of Chemistry and Biochemistry was awarded a grant from the Thalassemia Foundation of Canada to study molecular mechanisms of a virulence factor protein from an opportunistic pathogen that affects thalassemia patients.

3 Mar 2010

Inovio Biomedical introduces new CELLECTRA-SP series of hand-held, cordless electroporation devices

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, has unveiled its new CELLECTRA®-SP series of hand-held, cordless electroporation devices at the DNA Vaccines 2010 conference being held in New Orleans, LA.

3 Mar 2010

Aggressive treatment of anemia with ESAs may lower risk of death for dialysis patients: Study

Aggressive treatment of anemia with intravenous iron and drugs known as erythropoiesis-stimulating agents (ESAs) may lower the risk of death for dialysis patients with severe anemia - but also may increase the risk of death among patients with milder anemia, a new study led by a University of North Carolina at Chapel Hill epidemiologist suggests.

3 Mar 2010

G Protein News and Research

Brain study may lead to new forms of treatment for Alzheimer's disease

Exposure to blue-violet light may enhance cell growth in wound sites

Pycnogenol counteracts kidney damage due to hypertension

Cornell researchers find new protein that may help control mosquitoes from spreading diseases

Cystoscopy: Cost-effective method of detecting tumors

Belatacept drug can prevent graft rejection in kidney transplant recipients

Repligen acquires BioFlash

New chemical classes of preclinical compounds identified for Alzheimer’s disease

Researchers explore molecular origin of skin and hair to develop novel beauty products

Gene 'addiction' of leukaemia cells

Allergan celebrates 20th anniversary of BOTOX in Canada

Vaccine researchers at HZI find c-di-IMP molecule, more effective than known adjuvants

Concordia University Professor awarded grant to study molecular mechanisms of virulence factor protein

Inovio Biomedical introduces new CELLECTRA-SP series of hand-held, cordless electroporation devices

Aggressive treatment of anemia with ESAs may lower risk of death for dialysis patients: Study

MJFF for Parkinson's Research awards $500,000 grant to neuroscientist at Mayo Clinic

Pycnogenol counteracts kidney damage caused by hypertension, improves blood flow to the kidneys

Enlarged prostate: Dutasteride-tamsulosin combination therapy more effective

Findings could lead to new cancer-fighting drugs

Soluble fiber in oats, apples and nuts reduces inflammation; strengthens immune system

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News